* Ceftriaxone-Fresenius is indicated for the treatment of the following infections in adults and children including term neonates (from birth) :- Bacterial Meningitis- Community acquired pneumonia- Hospital acquired pneumonia- Acute otitis media- Intra-abdominal infections- Complicated urinary tract infections (including pyelonephritis)- Infections of bones and joints- Complicated skin and soft tissue infections- Gonorrhoea- Syphilis- Bacterial endocarditis* Ceftriaxone-Fresenius may be used:- For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults- For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.- For Pre-operative prophylaxis of surgical site infectionsIn the management of neutropenic patients with fever that is suspected to be due to a bacterial infectionIn the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above* Ceftriaxone-Fresenius should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.* Consideration should be given to official guidelines on the appropriate use of antibacterial agents.